@prefix this: <http://purl.org/np/RAXcamW9_pxb5PCXO3mSnZ_LsJd8Ndy4q-mBmXhOWXG9k> .
@prefix sub: <http://purl.org/np/RAXcamW9_pxb5PCXO3mSnZ_LsJd8Ndy4q-mBmXhOWXG9k#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_12134> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_12134>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00035>;
    a rdf:Statement;
    rdfs:label "desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5 desmopressin acetate injection will often maintain hemostasis in patients with hemophilia a during surgical procedures and postoperatively when administered 3 minutes prior to scheduled procedure desmopressin acetate injection will also stop bleeding in hemophilia a patients with episodes of spontaneous or trauma induced injuries such as hemarthroses intramuscular hematomas or mucosal bleeding desmopressin acetate injection is not indicated for the treatment of hemophilia a with factor viii coagulant activity levels equal to or less than 5 or for the treatment of hemophilia b or in patients who have factor viii antibodies in certain clinical situations it may be justified to try desmopressin acetate injection in patients with factor viii levels between 2 to 5 however these patients should be carefully monitored desmopressin acetate injection is indicated for patients with mild to moderate classic von willebrand s disease type i with factor viii levels greater than 5 desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von willebrand s disease during surgical procedures and postoperatively when administered 3 minutes prior to the scheduled procedure desmopressin acetate injection will usually stop bleeding in mild to moderate von willebrand s patients with episodes of spontaneous or trauma induced injuries such as hemarthroses intramuscular hematomas or mucosal bleeding those von willebrand s disease patients who are least likely to respond are those with severe homozygous von willebrand s disease with factor viii coagulant activity and factor viii von willebrand factor antigen levels less than 1 other patients may respond in a variable fashion depending on the type of molecular defect they have bleeding time and factor viii coagulant activity ristocetin cofactor activity and von willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved desmopressin acetate injection is not indicated for the treatment of severe classic von willebrand s disease type i and when there is evidence of an abnormal molecular form of factor viii antigen see warnings desmopressin acetate injection 4 mcg per ml is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus acetate injection is also available as an intranasal preparation however this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate these include poor intranasal absorption nasal congestion and blockage nasal discharge atrophy of nasal mucosa and severe atrophic rhinitis intranasal delivery may be inappropriate where there is an impaired level of consciousness in addition cranial surgical procedures such as transsphenoidal hypophysectomy create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:TreatmentIndication .
  
  <https://identifiers.org/drugbank:DB00035> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "Tr+CFzW3+NW49DgXr/hT4XxYhaLCQxZqB712sTe47GAq4AsXiRe28IsJtRwJQGvkR2KnsikylDxr24VkOGFGqgyGSnSAmL3QUdfXek/RojTqfaHkw0kTMZ4YsoAucxy40HkBl626dk0cji9waWK6afkWjIen5TY3cfyBdQHi4u0=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-06-18T08:59:37.678+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}